Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
- Registration Number
- NCT01363297
- Lead Sponsor
- Pfizer
- Brief Summary
The Phase 1 portion of this study will assess the safety, tolerability and efficacy at increasing dose levels of inotuzumab ozogamicin in subjects with CD22-positive relapsed or refractory adult acute lymphocytic leukemia (ALL) in order to select the recommended phase 2 dose (RP2D) and schedule. The Phase 2 portion of the study will evaluate the efficacy of inotuzumab ozogamicin as measured by hematologic remission rate (CR + CRi) in patients in second or later salvage status.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
- Subjects with CD22-positive ALL with either refractory disease (i.e. disease progression or no response while receiving their most recent prior anti-cancer therapy), or relapsed disease (i.e. response to their most recent prior anti-cancer therapy with subsequent relapse). Subjects enrolled in the Phase 2 portion of the study must be due to receive salvage 2 or later therapy.
- Subjects with Philadelphia chromosome-positive (Ph+) ALL must have failed standard treatment with at least one tyrosine kinase inhibitor.
- Adequate renal and hepatic function, and negative pregnancy test for women of childbearing potential.
- Subjects with isolated extramedullary relapse or active central nervous system (CNS) leukemia.
- Prior allogeneic hematopoietic stem cell transplant (HSCT) or other anti-CD22 immunotherapy within 4 months, or active graft versus host disease (GvHD) at study entry.
- Evidence or history of veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Inotuzumab Ozogamicin Inotuzumab Ozogamicin -
- Primary Outcome Measures
Name Time Method Percentage of Participants With Preliminary Satisfactory Response (Complete Response [CR], CR With Incomplete Count Recovery [CRi], Partial Response [PR], or Resistant Disease [RD]) Indicating Disease Stability After First Dose During Phase 1 Dose-Finding From screening to progressive disease or another induction therapy started, up to approximately 2 years CR was the disappearance of leukemia indicated by \<5% marrow blasts and absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was as for CR except with ANC \<1000/µL and/or platelets \<100,000/µL. PR was an improved or no worsening of acute lymphocytic leukemia indicated by no peripheral blood blasts, and/or at least a 50% decrease in the marrow blast percentage, compared to pre-treatment value, and marrow blast percentage ≥5% and less than or equal to (≤)25% and/or C2 extramedullary disease status. RD occurred if a participant survived ≥7 days following completion of initial treatment course and had persistent leukemia in the most recent peripheral blood smear or bone marrow and/or persistent disease involvement at any extramedullary site after completion of therapy.
Percentage of Participants With CR, CRi or PR During the Phase 1 Expansion Phase From screening to progressive disease or another induction therapy started, up to approximately 2 years CR was defined as a disappearance of leukemia as indicated by \<5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC \<1000/µL and/or platelets \<100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.
Percentage of Participants Reporting Dose Limiting Toxicities (DLTs) During the Phase 1 Dose-Finding Phase Cycle 1 DLT was any of the following in the first cycle \& attributable to inotuzumab ozogamicin: any greater than or equal to (≥) Grade 4 non-hematologic toxicity except nausea/vomiting (if manageable with supportive care), alopecia, \& toxicities secondary to neutropenia \& sepsis; prolonged myelosuppression (absolute neutrophil count \[ANC\] less than \[\<\] 500 per microliter \[/µL\] or platelet count \<25,000/µL in bone marrow with \<5 percent (%) blasts \& no evidence of leukemia more than 45 days beyond the most recent dose of test article); any Grade 3 non-hematologic toxicity (excluding toxicities such as alopecia or those secondary to neutropenia \& sepsis) not resolving to ≥ Grade 2 within 7 days of the most recent dose of test article or was clinically significant irrespective of duration; any ≥ Grade 3 elevation of alanine aminotransferase, aspartate aminotransferase or bilirubin lasting ≥7 days; any test article related toxicity resulting in permanent discontinuation of test article.
Percentage of Participants With CR or CRi During Phase 2 From screening to progressive disease or another induction therapy started, up to approximately 2 years CR was defined as a disappearance of leukemia as indicated by \<5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC \<1000/µL and/or platelets \<100,000/µL.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Who Had a Post-Treatment Stem-Cell Transplant (SCT) Up to approximately 2 years from first dose Post-treatment SCT rate was defined as the percentage of participants who underwent SCT following treatment with inotuzumab ozogamicin.
Overall Survival (OS) Up to approximately 2 years from first dose OS was defined as the time from Cycle 1 Day 1 to date of death due to any cause. If death was not documented, censoring occurred at the date at which the participant was last known to be alive.
Time to Remission for Participants Who Achieved CR or CRi Up to approximately 2 years from first dose Time to remission was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic remission (CR or CRi) in participants achieving remission during study therapy.
Progression Free Survival (PFS) Up to approximately 2 years from first dose PFS was defined as the time from Cycle 1 Day 1 to first documentation of PFS event (earliest date of objective progression \[PD\], treatment discontinuation due to global deterioration of health status, subsequent induction or transplant after best response of PR or resistant disease, relapse after CR or CRi, or death due to any cause). Participants last known to be 1) alive and 2) without a PFS event, were censored at the date of the last disease assessment that verified lack of event.
Duration of Remission (DoR1) for Participants Who Achieved CR or CRi Up to approximately 2 years from first dose DoR1 was defined for participants who responded as the time from the date of first documentation of Complete Hematologic Response (CR or CRi) to the date of the first documentation of relapse after CR or CRi, treatment discontinuation due to global deterioration of health status) or to death due to any cause. Participants last known to be 1) alive and 2) without a DoR1 event, were censored at the date of the last disease assessment that verified lack of event.
Duration of Response (DoR) for Participants Who Achieved CR/CRi or PR Up to approximately 2 years from first dose DoR was defined for participants who respond as the time from the date of first documentation of Hematologic Response (CR, CRi, or PR) to the date of the first documentation of DoR event (earliest date of PD, treatment discontinuation due to global deterioration of health status, first induction therapy or transplant after PR, relapse after CR or CRi or death due to any cause). Participants last known to be 1) alive and 2) without a DoR event, were censored at the date of the last disease assessment that verified lack of event.
Percentage of Participants With CR, CRi or PR in Phase 2 From screening to progressive disease or another induction therapy started, up to approximately 2 years CR was defined as a disappearance of leukemia as indicated by \<5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC \<1000/µL and/or platelets \<100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.
Number of Participants With Minimal Residual Disease (MRD) Negativity in Participants Achieving CR and CRi From screening to progressive disease or another induction therapy started, up to approximately 2 years MRD negativity was defined as \<0.01% mononuclear cells.
Time to Response for Participants Who Achieved CR/CRi or PR Up to approximately 2 years from first dose Time to response was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic response (CR, CRi, or PR).
Time to MRD Negativity for Participants Who Achieved CR or CRi Screening, Day 21 of Cycles 1 to 6 and up to 4 to 6 weeks after the last dose (up to 34 weeks) Time to MRD negativity was defined as the time from the date of first dose of study drug to the date of first documentation of MRD negativity.
Percentage of Participants With CR or CRi by Cytogenetic Category From screening to progressive disease or another induction therapy started, up to approximately 2 years CR was defined as a disappearance of leukemia as indicated by \<5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC \<1000/µL and/or platelets \<100,000/µL.
Duration of Follow-Up From first dose up to approximately 2 years Duration of follow-up was defined as the time from the date of first dose of study drug to the date of last contact for participants known to be alive.
Percentage of Cluster of Differentiation-22 Positive (CD22+) Leukemic Blasts in Abnormal B Cells in Blood by Visit Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4 CD22+ leukemic blasts assessed in abnormal B cells from blood (data from central laboratories only).
Percentage of CD22+ Leukemic Blasts in Abnormal B Cells in Bone Marrow by Visit Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4 CD22+ leukemic blasts assessed in abnormal B cells from bone marrow (data from central laboratories only).
Messenger Ribonucleic Acid (mRNA) Gene Expression Predose and postdose on Days 1 and 15 of Cycle 1 Optional blood samples for pharmacogenomic parameters were collected during Cycle 1 prior to the start of the inotuzumab ozogamicin infusion (0 hours) and 1 hour post-dose (original Final Protocol and Protocol Amendments 1 and 2) or 3 hours post-dose (Protocol Amendments 3 and 4) on Day 1 and Day 15 from those participants who provided consent. Gene expression analysis of samples collected pre- and post-dosing was performed using 96-gene TaqMan® low density array cards to examine the concordance between clinical outcome and expression of genes such as those involved in DNA damage response, apoptosis, B-cell antigen expression, glutathione metabolism, drug transport and the phosphoinositide 3-kinase/mammalian target of rapamycin pathway. Expression for each gene was reported as a normalized value, 2\^-change in (∆) threshold cycle (Ct), where ∆Ct is Ct\^target gene minus Ct\^reference genes, averaged.
Trial Locations
- Locations (15)
Stanford Unversity Cancer Clinical Trials Office
🇺🇸Palo Alto, California, United States
Stanford Cancer Institute
🇺🇸Stanford, California, United States
Stanford Unversity Hospital and Clinics, CTRU
🇺🇸Palo Alto, California, United States
Massachusetts General Hospital (MGH)
🇺🇸Boston, Massachusetts, United States
Brigham and Women's Hospital (BWH)
🇺🇸Boston, Massachusetts, United States
The University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Karmanos Cancer Institute at Farmington Hills
🇺🇸Farmington Hills, Michigan, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
City of Hope National Medical Center
🇺🇸Duarte, California, United States
Stanford University Hospital and Clinics
🇺🇸Stanford, California, United States